Programme
The Reception | Tuesday 25th May 2021 | 18:00 - 20:00
The Danish Embassy, The Ambassador's Residence, 2 Hans Street, London, SW1X ONJ
____________________________________________________________________
The Conference | Wednesday 26th May 2021 | 08:15 - 18:30
8:15 Registration opens, full continental breakfast is served
9:00 Welcome
Mattias Johansson, Director, Ezenze Ltd, Anglonordic Conference Founder
Morning session Chaired by Mary Clark, Managing Director, Optimum Strategic Communications
9:05 Keynote
9:30 What’s hot and what's simmering? - Investment Panel Discussion
Chaired by: Amber Tong, Endpoints
Panellists: Hakan Goker, M Ventures | Nanna Luneborg, Novo Ventures | Stephan Christgau, EIR Ventures
Europe’s leading investors will provide an overview of their outlook on the market, as well as current and future trends that are driving investment in the healthcare sector.
10:30 Coffee
11:00 Company Presentations
Biotech Investment Room and Technology Room
Presentations include:
Adare Pharmaceuticals, a global, technology-driven CDMO providing turnkey product development through commercial manufacturing expertise focused on oral dosage forms for the Pharmaceutical, Animal Health and OTC markets.
Myxobiotics, developing the cystobactamid broad-spectrum anti-bacterial for treatment of cUTI and possibly HAP/VAP.
Macrophage Pharma, focused on treating human disease by reprogramming macrophage function through transcriptional reprogramming and targeted drug-delivery leveraging proprietary Esterase Sensitive Motif™ (ESM™) platform.
VAXIMM, a privately held Swiss/German biotech company that is developing oral T-cell immunotherapies
Apply to pitch here.
____________________________________________________________________
12:30 - 13:30 Networking Lunch
____________________________________________________________________
Afternoon session
13:30 DDR Therapeutics - Panel discussion
Chaired by: Lucie Ellis, In Vivo
Panellists: Niall Martin, Artios Pharma | Andree Blaukat, Merck KGaA, Darmstadt, Germany | Simon Boulton, Artios Pharma and Francis Crick Institute
A panel of industry experts and investors will discuss this exciting field of biology, clinically validated by the first-generation PARP inhibitors currently on the market. Listen to the panel discuss the strength of DNA Damage Response as an investment opportunity and how this hot area of biology will rapidly impact the clinic.
14:30 Company Presentations
Biotech Investment Room and Technology Room
Presentations: to be announced soon! Apply to pitch here.
15:45 Coffee
16:00 Building your Board - Structure, Diversity, Success - Panel Discussion
Chaired by: Maureen Coleman, PIR International
Panellists: Patrick Vink, NED - NMD/F2G | Eva-Lotta Allan, Independent Board Director C4X Discovery, Almirall, Aleta Biotherapeutics, Crescendo Biologics, Targovax
Join our panel of internationally experienced Board profiles from the industry as they discuss the importance of an agile, forward-looking, tenacious and diverse Board for success in the healthcare sector. Amongst them, our panel have experienced what an impactful Board looks like and the momentum it can give any growth stage life science business for success.
16:45 If I knew then what I know today - Panel Discussion
Mike Ward Chairs a panel of industry executives who will reflect on previous experiences and discuss key learnings from their careers.
17.45 Conclusions
17.55 - 18:45 Drinks Reception
Hosted by Mattias Johansson, Director, Ezenze Ltd
____________________________________________________________________
1:1 meetings take place throughout the day and are pre-booked online.
Login to add your profile, bookmark prospects and book meetings.
____________________________________________________________________
Attendees
Over 60 Investors confirmed so far:
Advent Life Science, Albion Technology & General VCT, Alpha Blue Ocean, Alpha Bronze Life Sciences Opportunities Fund, Apollo Ventures, Aratus Capital, Arix Bioscience, Arvic AG, Axilium Holding, Axon Capital Partners, Bioscience Managers, Biotechnology Business Institute, Bond Asian Ventures, Cascara Ventures Bvba, Catapult Ventures, DeBere Capital Partners, Deep Science Ventures, Eli Lilly, ESM Biotech, Esperante, GL Capital, GSK, GreenSky Capital, Helsinn Investment Fund, Hermes Partners Intl, Ignite Capital Partners, Inkef Capital, Innovate UK, IP Group, IPF Partners, Kreos Capital, Kurma Partners, Longacre Funding Partners, Lundbeckfonden Emerge, Lundbeckfonden Ventures, Luminous Ventures, M Ventures, Mercia Asset Management, Momentum Biotech, MVM Partners, NeoMed, Newables, Norgine Ventures, o2h Ventures, Optum Ventures, oxford technology 3, Panakes Partners, Pontifax, Questra, Rosetta Capital, Seroba Life Sciences, Seventure Partners, SHS, Swelife International, Syncona, Syndicate Room, Trilantic Europe, UCB Ventures, UK Innovation & Science Seed Fund, Xeraya Capital and XOventure.
